PRMT5 Inhibitor Compounds Modulating Enzymatic Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective inhibitors for Protein Arginine Methyltransferase 5 (PRMT5), a chromatin-modifying enzyme implicated in various human diseases such as proliferative, metabolic, and blood disorders, necessitating the development of small molecules that can specifically inhibit PRMT5 activity.
Innovation Solution
Development of compounds with specific chemical formulas (e.g., Formula (I A), (I B), and (I D) that act as inhibitors of PRMT5, capable of modulating its activity by contacting PRMT5 in cells or tissues, thereby inhibiting its enzymatic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target PRMT5, then therapeutic efficacy for PRMT5-mediated disorders is improved, but drug specificity and selectivity become critical challenges
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular regions or characteristics of PRMT5. The compounds contain specific structural elements (such as heterocyclic rings, linker groups, and terminal moieties) that are optimized to interact with unique aspects of the PRMT5 active site, thereby achieving selective inhibition while avoiding off-target effects on other methyltransferases.
Solution Approach 2:
The patent employs parameter changes by systematically varying key molecular parameters of the inhibitor compounds, including the types of heterocyclic rings (R1, R2, R3), linker lengths and compositions (L1, L2, L3), and terminal group structures. These parameter optimizations allow fine-tuning of binding affinity and selectivity for PRMT5 versus other enzymes, resolving the contradiction between efficacy and specificity.
2Adaptability or versatility
If broad-spectrum methyltransferase inhibition is achieved, then multiple disease pathways are addressed, but specificity for PRMT5 is reduced
Solution Approach 1:
The patent applies universality by designing a compound scaffold that can address multiple disease pathways involving PRMT5 dysregulation, including proliferative disorders, metabolic disorders, and blood disorders. The core molecular structure provides a universal platform that maintains PRMT5 selectivity while being applicable to various disease contexts through appropriate compound selection from the series.
3Strength
If complex molecular structures are designed for high PRMT5 affinity, then binding strength is improved, but drug development complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a heterocyclic ring system (R1, R2, or R3), a linker region (L1, L2, or L3), and a terminal moiety. This modular segmentation allows for systematic optimization of each component's contribution to binding affinity while maintaining overall structural manageability and facilitating rational drug design.
Solution Approach 2:
The patent employs intermediary elements in the form of linker groups (L1, L2, L3) that connect the heterocyclic core to terminal functional groups. These intermediary linkers serve as flexible connectors that can be optimized for length, composition, and flexibility to achieve optimal binding geometry and affinity while keeping the overall molecular structure tractable for synthesis and development.
Data Source
AI summary
Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.